Security key
29664W105
- Security type / class
- Equity / COM
- Total 13F shares
- 111,244,473
- Total 13F value
- $160,207,390
- Share change
- -14,896,172
- Put/Call ratio
- 394%
- SEC-reported price per share
- $1.44
- Number of holders
- 183
- Value change
- -$24,300,645
- Number of buys
- 76
- Number of sells
- 84
- Shares outstanding
- 275,740,714
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
183
Top holders
10
ESPR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Esperion Therapeutics, Inc. SEC filings
Esperion Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29664W105
Recent filing periods:
Ownership snapshot
Top reported holders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BB BIOTECH AG
Disclosed value leader
WASATCH ADVISORS LP
Comparable rows
15/15
Latest evidence
04 Mar 2025
13D/G
13F
Lead comparable stake: 4.9%
13D/G row: BB BIOTECH AG
Showing 1-6 of 15 holder rows.
Quick read
BB BIOTECH AG leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BB BIOTECH AG's linked filing trail.
Comparable ownership
Top 5
BB BIOTECH AG
4.9%
WASATCH ADVISORS LP
8.9%
BlackRock, Inc.
5.2%
VANGUARD GROUP INC
4.2%
Bellevue Group AG
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BB BIOTECH AG |
13D/G
|
4.9%
|
$8,821,598
9,694,064 shares
|
-$227,500 | 04 Mar 2025 |
| WASATCH ADVISORS LP |
13F
Company
|
8.9%
|
$53,860,968
24,482,258 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
5.2%
|
$31,317,931
14,235,423 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
4.2%
|
$25,774,646
11,715,748 shares
|
— | 31 Dec 2024 |
| Bellevue Group AG |
13F
Company
|
3.6%
|
$21,876,941
9,944,064 shares
|
— | 31 Dec 2024 |
| MORGAN STANLEY |
13F
Company
|
2.3%
|
$13,880,631
6,309,377 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
183
Shares
111,244,473
Rows available
183
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
188
Q1 2025 holders
183
Holder diff
-5
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend